P3-454: Electromagnetic field therapy in Alzheimer’s disease using DC electromagnetic field therapy: A pilot study, review of the literature, hypothesis of therapeutic action and future research proposal

Abstract

The etiology of Alzheimer's diseases is still unknown but the valid diagnosis of AD requires the presence of neurofibrillary tangles, β amyloid and granulovacuolar degeneration (GVD) in neurons of patient's brains. Research by Alan MacDonald MD and later by Judith Miklossy MD has suggested Borrelia burgdorferi persist in the brain in chronic Lyme neuroborreliosis as the infectious etiology in Alzheimer's disease. Inflammation in the form of reactive astrocytes and microglia is thought to play an important role in Alzheimer's disease pathogenesis. To increase cognition and reduce inflammation. Magnetic Molecular Energizer consists of two large and strong non–pulsing DC electromagnet field (EMF) therapy with the patient lying in a focal point between the two electromagnets. When the patient is treated with the MME device there is a temporary increase in the magnetic force on the atoms of the body resulting in a higher velocity and precession of certain orbiting electrons resulting in enhanced electron transfer and chemical reactions. Alzheimer's disease (AD) is a neurodegenerative disease secondary to oxidative stress, which has been found to cause apoptosis of neurons. It is associated with genetic and environmental factors such as exposure to pesticides and heavy metals with subsequent depletion of mitochondrial protective enzymes, superoxide dismutase and glutathione via free radical toxicity. Seven AD patients were treated with MME from 12 to 330 hours under an IRB approved protocol. All seven AD patients after MME improved in cognition and memory. However, the previous enhanced cognition deteriorated after 6 months of completing the DC EMF therapy in most patients. MME is hypothesized to up–regulate superoxide dismutase and glutathione and eliminate heavy metals. It may even drive Borrelia Bb from the tissues and up–regulate endogenous stem cells. In order to have sustained improvement in Alzheimer patients suspected of having ongoing bacterial infection with Borrelia, long term antibiotic therapy (6 months) will be instituted along with 200 hrs of DC EMF therapy. A parallel trial of Alzheimer patients diagnosed with Lyme by ILADS criteria with 6 months of Doxycycline/ Tindazole without DC electromagnetic therapy is also planned.